Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07009860 · ClinicalTrials.gov registry record · Phase 2

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

A Phase 2 study of Alcohol Liver Disease, sponsored by Altimmune.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
20
Study locations

NCT07009860: Recruiting Phase 2 study of Alcohol Liver Disease, sponsored by Altimmune.

NCT07009860 is a Phase 2 study of Alcohol Liver Disease that is actively recruiting participants, run by Altimmune. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07009860, a Phase 2 study of Alcohol Liver Disease, is actively recruiting participants, sponsored by Altimmune.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly

Conditions Studied

Alcohol Liver Disease

Interventions

  • OTHER Placebo
  • DRUG Pemvidutide

Study Locations (20)

Florida

  • Altimmune Clinical Study Site - Bradenton
  • Altimmune Clinical Study Site - Doral
  • Altimmune Clinical Study Site - Doral
  • Altimmune Clinical Study Site - Fort Myers
  • Altimmune Clinical Study Site - Miami
  • Altimmune Clinical Study Site - Miami
  • Altimmune Clinical Study Site - Miami Lakes
  • Altimmune Clinical Study Site - Naples
  • Altimmune Clinical Study Site - Orlando
  • Altimmune Clinical Study Site - Port Orange

Arizona

  • Altimmune Clinical Study Site - Peoria
  • Altimmune Clinical Study Site - Tucson
  • Altimmune Clinical Study Site - Tuscon

California

  • Altimmune Clinical Study Site - Fresno
  • Altimmune Clinical Study Site - La Jolla
  • Altimmune Clinical Study Site - Pasadena

Arkansas

  • Altimmune Clinical Study Site - North Little Rock

Colorado

  • Altimmune Clinical Study Site - Englewood

Georgia

  • Altimmune Clinical Study Site - Atlanta

Indiana

  • Altimmune Clinical Study Site - Indianapolis

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-06-16
Est. Completion 2027-08-31
Phase Phase 2
Altimmune

16 total trials

What NCT07009860 shows while recruiting

NCT07009860 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).

The record links to 1 condition, with Alcohol Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07009860 names 20 study sites across 7 states, led by Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT07009860 about?

NCT07009860 is a clinical study titled "RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly

What is the current status of trial NCT07009860?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-06-16. Estimated completion is 2027-08-31.

What conditions does trial NCT07009860 study?

This clinical trial studies the following conditions: Alcohol Liver Disease.

What interventions are being tested in trial NCT07009860?

The interventions under investigation include: Placebo (OTHER), Pemvidutide (DRUG).

Who is sponsoring clinical trial NCT07009860?

This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07009860 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alcohol Liver Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07009860's enrollment target sits among peer trials

100 672nd of 2000 higher than 1,264 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07009860

Source: ClinicalTrials.gov NCT07009860, the US trial registry maintained by the National Library of Medicine. NCT07009860 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.